Difference between revisions of "Carmustine (BCNU)"

Revision as of 15:45, 28 January 2019

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.^[1]^[2]
Route: IV
Extravasation: vesicant/irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Diseases for which is was used

Multiple myeloma

Patient drug information

History of changes in FDA indication

3/7/1977: Initial FDA approval

Also known as

Generic names: BCNU, bischloroethylnitrosourea, carmustin
Brand names: Becenun, BiCNU, Carmubris, Gliadel, Gliadel Wafer, Leucerom, Nitrourean, Nitrumon

References

[insert-1] 1.0 ^1.1 Carmustine (BiCNU) package insert

[2] Carmustine (BiCNU) package insert (locally hosted backup)

[3] Carmustine (BiCNU) patient drug information (Chemocare)

[4] Carmustine (BiCNU) patient drug information (UpToDate)

[1]

[2]

[3]

[4]